The Unfolding Crisis of Long Covid: Five Years On, Patients Demand Answers and Effective Treatment
Paris, France – As we move further into 2026, the shadow of the Covid-19 pandemic continues to lengthen, not through latest waves of acute infection, but through the persistent and debilitating condition known as Long Covid. Frustration is mounting among patients worldwide, many of whom find themselves grappling with a complex array of symptoms years after their initial infection. The lack of definitive understanding regarding the causes of Long Covid, and the corresponding absence of targeted treatments, is fueling a growing sense of abandonment. Recent demonstrations in Paris, outside the Hôtel-Dieu (AP-HP), underscore the urgency of the situation, with patients voicing their concerns about being dismissed as psychologically unwell rather than receiving the medical attention they desperately need. The core issue remains: despite extensive research, a clear path to effective management of this chronic condition remains elusive.
Long Covid, also known as post-Covid-19 condition, is characterized by a wide range of symptoms that persist for weeks, months, or even years after the initial SARS-CoV-2 infection. These symptoms can include fatigue, shortness of breath, cognitive dysfunction (“brain fog”), muscle pain, and a host of other debilitating issues. Estimates of prevalence vary, largely due to differing definitions and diagnostic criteria, but the World Health Organization (WHO) estimates that approximately 6% of individuals infected with Covid-19 will develop a prolonged form of the illness. This translates to millions of people globally struggling with a condition that significantly impacts their quality of life and ability to work.
The search for answers has been intense, with researchers exploring a multitude of potential mechanisms driving Long Covid. These include the persistence of the SARS-CoV-2 virus in the body, chronic inflammation, immune dysregulation, and even microclots affecting blood flow. However, translating these theoretical understandings into effective therapies has proven remarkably challenging. Mireille Laforge, a researcher at the Centre national de la recherche scientifique (CNRS) in France, recently stated that numerous clinical trials worldwide have, to date, yielded no significant breakthroughs. “Notice more than a dozen therapeutic clinical trials launched around the world, but we are facing a total failure,” she noted during a press conference organized by the ANRS Maladies infectieuses émergentes (ANRS MIE). This lack of progress is particularly disheartening given the substantial research effort dedicated to understanding post-infectious syndromes, a field historically underfunded and understudied.
The Complexity of Long Covid: Is It One Condition or Many?
A growing body of evidence suggests that Long Covid may not be a single, monolithic condition, but rather a spectrum of overlapping syndromes with different underlying causes and, potentially, different treatment approaches. Laforge’s assessment highlights the need to refine our understanding of the disease’s heterogeneity. “We are not aiming well enough,” she explained, suggesting that a more nuanced approach is required to identify specific subtypes of Long Covid and tailor treatments accordingly. This perspective is gaining traction within the scientific community, prompting a re-evaluation of research strategies.
Adding to the complexity, a dissenting school of thought is advocating for a shift in focus from identifying physiological causes to understanding the lived experience of symptoms. In a November 2025 Le Monde article, a group of researchers led by psychiatrist Cédric Lemogne argued for a “science of symptoms,” emphasizing the importance of addressing the psychological and neurological consequences of Long Covid, even in the absence of a clear understanding of the underlying biological mechanisms. This approach has sparked considerable debate, with some patient advocacy groups expressing concern that it could lead to the dismissal of their physical symptoms as purely psychological.
Lemogne, who is involved in a Long Covid care pathway at Hôtel-Dieu, argues that while the initial trigger for Long Covid is often physical, the factors perpetuating symptoms may be more complex, involving psychological and cognitive components. He emphasizes that psychotherapies and physical rehabilitation have shown some modest benefits in improving the quality of life for patients, as demonstrated in a 2025 study published in the BMJ. However, he acknowledges that these interventions are not a cure and that further research is needed to develop more effective treatments.
The Controversy Surrounding Psychological Explanations
The suggestion that psychological factors play a significant role in Long Covid has been met with resistance from some patient groups, who fear that it will be used to invalidate their experiences and deny them appropriate medical care. These concerns are fueled by a history of medical gaslighting and the stigmatization of chronic illnesses. Lemogne defends his position, stating that he is not advocating for a purely psychological explanation, but rather recognizing the interplay between physical and psychological factors in the perpetuation of symptoms. He also suggests that dismissing the potential benefits of psychological interventions could be detrimental to patients who might benefit from them.
The debate over the causes and treatment of Long Covid highlights the challenges of navigating a complex and evolving medical landscape. The lack of a single, unifying explanation for the condition underscores the need for a multidisciplinary approach that integrates insights from various fields, including virology, immunology, neurology, and psychiatry. It emphasizes the importance of patient-centered care that acknowledges the individual experiences and needs of those affected by Long Covid.
The ongoing research into Long Covid is also informing our understanding of other post-infectious syndromes, such as those associated with Lyme disease. Both conditions share similarities in their chronic, multi-systemic nature and the challenges they pose to diagnosis and treatment. The increased attention and funding directed towards Long Covid research may ultimately benefit patients with other post-infectious illnesses as well.
Looking Ahead: The Need for Continued Research and Patient Support
As we enter 2026, the situation surrounding Long Covid remains critical. Millions of people continue to suffer from the long-term effects of the pandemic, and the lack of effective treatments is a major source of frustration and despair. Continued investment in research is essential to unravel the complexities of this condition and develop targeted therapies. This research should focus on identifying biomarkers, understanding the underlying mechanisms, and evaluating the effectiveness of different interventions.
In addition to research, increased support for patients is crucial. This includes access to specialized clinics, multidisciplinary care teams, and mental health services. It also involves addressing the social and economic consequences of Long Covid, such as job loss and disability. Patient advocacy groups play a vital role in raising awareness, advocating for policy changes, and providing support to those affected by the condition.
The experience of the Covid-19 pandemic has underscored the importance of preparedness for future public health emergencies. Investing in research on post-infectious syndromes and developing robust surveillance systems are essential steps to mitigate the long-term consequences of emerging infectious diseases. The lessons learned from Long Covid will undoubtedly inform our response to future health crises.
The next major checkpoint in the Long Covid research landscape is the anticipated release of preliminary data from several large-scale clinical trials evaluating novel therapeutic approaches in the fall of 2026. These trials, focusing on interventions targeting inflammation, immune dysregulation, and viral persistence, offer a glimmer of hope for patients who have been waiting years for effective treatment options. Stay informed about the latest developments by consulting reputable sources such as the World Health Organization and the National Institutes of Health. Share your experiences and connect with others affected by Long Covid – your voice matters.